20 G vitrectomy safe and effective technique in vitreoretinal surgery

Article

Using twenty-gauge transconjunctival sutureless vitrectomy in vitreoretinal surgery is a safe and effective treatment for a variety of vitreoretinal pathologies

Using twenty-gauge transconjunctival sutureless vitrectomy in vitreoretinal surgery is a safe and effective treatment for a variety of vitreoretinal pathologies, according to a study featured in Retina.

The retrospective study led by Dr Oriel Spierer, Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Israel, reviewed the charts of 102 consecutive patients who experienced 20-gauge transconjunctival sutureless vitrectomy performed by a single surgeon.

All patients were assessed preoperatively and 1 day, 1 month and 3 months postoperatively. The main outcome measures included intraoperative/postoperative intraocular pressure and Snellen visual acuity compared to preoperative data.

Findings revealed that two patients needed suturing of 1 scleretomy due to postoperative leakage. The mean preoperative visual acuity was 1.1 ± 0.6. Three months postoperatively the mean visual acuity was 0.8 ± 0.5.

Mean preoperative intraocular pressure was 14.7 ± 5.1 mmHg, whilst postoperatively it was 14.2 ± 5.5 mmHg and 14.6 ± 4.3 mmHg at day 1 and day 7, respectively.

In three patients hypotony was found on the first day postoperatively, but intraocular pressure returned to normal within a week. There was no record of postoperative endophthalmitis or retinal detachment in any of the patients.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.